Related Experiment Video
Updated: Mar 1, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Current options to manage Waldenström's macroglobulinemia.
Giulia Benevolo1, Maura Nicolosi1, Elisa Santambrogio1
1a Division of Hematology , AOU Città della Salute e della Scienza , Torino , Italy.
Waldenström's macroglobulinemia (WM) treatment involves standard therapies like RCD and BRD, alongside new drugs such as ibrutinib. While effective, WM remains incurable, necessitating ongoing clinical trial participation.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Waldenström's macroglobulinemia (WM) is a rare, incurable B-cell lymphoma.
- Current standard of care lacks consensus, with various agents used.
- Median survival for symptomatic patients is 5-10 years.
Purpose of the Study:
- To review standard therapies for WM.
- To discuss novel therapeutic agents under investigation for WM.
- To provide expert commentary on current and emerging WM treatments.
Main Methods:
- Review of existing literature on WM therapies.
- Analysis of clinical data for standard and investigational drugs.
- Expert opinion on treatment efficacy and safety.
Main Results:
- Rituximab/Cyclophosphamide/Dexamethasone (RCD) is effective and safe for first-line WM treatment.
- Bendamustine/Rituximab (BR) or Bortezomib/Rituximab/Dexamethasone (BRD) offer durable responses.
- Ibrutinib is approved for primary and relapsed therapy; Carfilzomib-based therapy is an emerging option.
Conclusions:
- WM remains an incurable disease despite encouraging treatment results.
- New therapeutic options are continuously needed.
- Encouraging patient participation in clinical trials is crucial for advancing WM treatment.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Myocarditis III: Medical Management
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Rheumatic Heart Disease III: Medical Management